Drug intelligence / Profile preview

Uralbu

Development stage: Phase 1
Lead developer: MMC Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Uralbu is an oral urinary alkalizer marketed by MMC Pharmaceuticals (formerly MMC Healthcare). It contains disodium hydrogen citrate as its active ingredient. The medication is primarily used to treat urinary tract infections (UTIs) by neutralizing excess acid in the urine, which helps relieve the burning sensation during micturition. It is also indicated for the management of kidney stones (urolithiasis) and gout, as it promotes the dissolution of uric acid stones and prevents their recurrence by maintaining an alkaline urinary environment. Uralbu is commonly prescribed for symptomatic relief in patients with dysuria and is part of MMC's Urocare and Ferticare product lines, often used to manage urinary symptoms during pregnancy.

Brand names: Uralbu
Other names: Disodium hydrogen citrateSodium acid citrate

Beyond the preview

Go deeper on Uralbu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Uralbu.

Explore the full profile